Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Feb;65(2):e7-e13.
doi: 10.1111/epi.17854. Epub 2023 Dec 21.

Fenfluramine below the age of 2 years in Dravet syndrome: What about safety and efficacy?

Nicola Pietrafusa  1 , Marina Trivisano  1 , Susanna Casellato  2 , Cinzia Correale  1 , Simona Cappelletti  1 , Paola De Liso  1 , Ilaria Onida  2 , Stefano Sotgiu  2 , Ambra Butera  3 , Nicola Specchio  1 , Federico Vigevano  4
Affiliations

Fenfluramine below the age of 2 years in Dravet syndrome: What about safety and efficacy?

Nicola Pietrafusa et al. Epilepsia. 2024 Feb.

Abstract

Dravet syndrome (DS) is a rare developmental and epileptic encephalopathy. Infants with DS are especially vulnerable to the detrimental effects of prolonged and frequent seizures on development. Fenfluramine (FFA) is approved for the treatment of DS in patients aged 2 years and older. This study aims to evaluate the safety and efficacy of FFA in patients with DS younger than 2 years. We analyzed safety, tolerability, seizure, and neuropsychological outcome in a real-world setting. Developmental profile was investigated using Griffiths Mental Development Scales (GMDS). Five patients received FFA at a mean age of 14.9 months (9.6-18.6). Median follow-up was 13 months (interquartile range [IQR] = 12.9-24.4). All patients showed good tolerance to FFA. No significant variation of body mass index or echocardiographic issue was observed. Monthly median convulsive seizure frequency (MCSF) was 1.71 (IQR = 1.56-3.27) at the 6-month baseline period and .92 (IQR = .43-1.28) at last follow-up, with a median 54.43 (IQR = 40.91-60.83) percentage reduction in MCSF. Two of five patients had a performance improvement on GMDS subscales. Overall, the use of FFA below the age of 2 years in our small sample of patients was safe and represents a promising opportunity for seizure control and for protection of the neurodevelopmental outcome.

Keywords: Dravet syndrome; epilepsy; fenfluramine; infancy; neurodevelopment.

PubMed Disclaimer

References

REFERENCES

    1. Zuberi SM, Wirrell E, Yozawitz E, Wilmshurst JM, Specchio N, Riney K, et al. ILAE classification and definition of epilepsy syndromes with onset in neonates and infants: position statement by the ILAE task force on nosology and definitions. Epilepsia. 2022;63:1349-1397.
    1. Nabbout R, Chemaly N, Chiron C, Kuchenbuch M. Safety considerations selecting antiseizure medications for the treatment of individuals with Dravet syndrome. Expert Opin Drug Saf. 2021;20:561-576.
    1. Wirrell EC, Hood V, Knupp KG, Meskis MA, Nabbout R, Scheffer IE, et al. International consensus on diagnosis and management of Dravet syndrome. Epilepsia. 2022;63:1761-1777.
    1. Bertuccelli M, Verheyen K, Hallemans A, Sander JW, Ragona F, Bisiacchi P, et al. Deconstructing Dravet syndrome neurocognitive development: a scoping review. Epilepsia. 2021;62:874-887.
    1. Schraegle WA, Titus JB. Executive function and health-related quality of life in pediatric epilepsy. Epilepsy Behav. 2016;62:20-26.

LinkOut - more resources